Issue 5/2023
Kolev, P., Borizanova, A., Kinova, Gudev, A.
Cardiology clinic at UMBAL, Tsaritsa Yoanna – ISUL“, Medical University – Sofia
To date, heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) represents approximately half of HF cases and proportion being classified as heart failure with preserved ejection fraction has increased the last decade, at the expense of patients with heart failure with reduced ejection fraction. The cause of heart failure with preserved ejection fraction (HFpEF) is incompletely understood and specific therapies are lacking. Follow-up studies of patients with evidence of heart failure with preserved ejection fraction are currently underway to investigate whether higher plasma levels of interleukin 6 (IL-6) are associated with an increased risk of developing new-onset heart failure over time of time and in particular in those with preserved ejection fraction. There is still no effective treatment for heart failure with preserved ejection fraction, but a number of targeted therapies are being developed with promising efficacy results. The aim of this review is to inform clinicians with the latest novelty in the approach to diagnosis and treatment of patients with heart failure with preserved ejection fraction.
Address for correspondence:
Kolev, P.
Clinic of Cardiology, UMHAT,, Queen Joanna – ISUL’’,
Medical University – Sofia
8, „Bialo more“, Str.
1527, Sofia
e-mail: peturkolev211@abv.bg